All In Biotech

NDA 022315 · Abbvie

Ozurdex

Dexamethasone · Intravitreal · Corticosteroid

Priority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Mar 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Jun 17, 2009

Approved uses

3

Original approval plus efficacy supplements

Registered trials

4,222

936 Phase 3, 495 recruiting

FAERS reports

297,995

251,860 serious, 48,238 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 11, 2026.

OZURDEX is a corticosteroid indicated for: The treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) ( 1.1 ) The treatment of non-infectious uveitis affecting the posterior segment of the eye ( 1.2 ) The treatment of diabetic macular edema ( 1.3 ) 1.1 Retinal Vein Occlusion OZURDEX ® (dexamethasone intravitreal implant) is indicated for the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). 1.2 Posterior Segment Uveitis OZURDEX is indicated for the treatment of non-infectious uveitis affecting the posterior segment of the eye. 1.3 Diabetic Macular Edema OZURDEX is indicated for the treatment of diabetic macular edema.

Mechanism: Dexamethasone, a corticosteroid, has been shown to suppress inflammation by inhibiting multiple inflammatory cytokines resulting in decreased edema, fibrin deposition, capillary leakage and migration of inflammatory cells.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • OZURDEX · DEXAMETHASONE 0.7MG · IMPLANT, INTRAVITREAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Dexamethasone" as an intervention, any sponsor and status, largest first.

All 4,222 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use22,933
  • fatigue17,499
  • diarrhoea17,302
  • plasma cell myeloma14,401
  • nausea14,181
  • pneumonia13,820
  • death13,532
  • drug ineffective13,296
  • neutropenia11,780
  • pyrexia11,109
  • thrombocytopenia10,774
  • dyspnoea10,386

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,561
20052,135
20061,096
2007875
20081,308
20091,923
20103,594
20115,449
20126,776
20136,788
20148,419
201517,458
201615,932
201717,974
201823,448
201923,468
202025,390
202129,153
202227,447
202324,384
202421,709
202518,734
202612,972

Recalls

1 FDA enforcement reports for this application.

  • Dec 20, 2018 · Class II · Completed

    GMP Deviations: A silicone particulate was noted in Ozurdex.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ozurdex (Dexamethasone)

2024 spending

$1.9M

Beneficiaries

622

1,126 claims

Per beneficiary

$3,012

$1,354.66 per unit

View as table
YearSpending
2020$754,775
2021$762,513
2022$1,505,808
2023$1,927,283
2024$1,873,498

Part B: Ozurdex (Dexamethasone) · HCPCS J7312

2024 spending

$48.0M

Beneficiaries

15,038

32,147 claims

Per beneficiary

$3,189

2024 ASP limit $205.60 per unit

View as table
YearSpending
2020$50,706,134
2021$51,773,257
2022$52,772,487
2023$50,941,464
2024$47,962,972

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7,426 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.